ラット同種拒絶反応におけるマクロファージ・単球エフェクターの関与新しい単球エフェクターSpontaneousPlaque・Forming Cell について

概要

論文の詳細を見る
ラット同種皮膚および心移植において,非特異的溶血活性を示すSPFC単球エフェクターの産生応答は,拒絶反応に一致してみられた.そのピーク時のSPFC産生数は組織適合性の差による違いとよく相関していることから,SPFCの単球は移植免疫反応とよく連動した応答を示すエフェクターとみなされるSpontaneous plaque-forming cell, SPFC, is a new hemolytic effector of monocytes, which is generated 6 to 7 days after antigen unstimulation or stimulation in man. SPFC is also detected in rats. A significant concomitant response of the SPFC, in number of SPFC at the peak response around the rejection day, and histoincompatibility of allogeneic combinations in skin or heart allograft transplantation of rats was found. Peak number of SPFC (28,850 + 1,343/10(6) on day 6 in H-1 incompatible combination (ACI-Lewis) was higher than that (11,606 + 4,235/10(6)) on day 10 in H-1 compatible combination (F344-Lewis) (p less than 0.05, Student'st-test). The day of peak SPFC response in each experimental group was also concordant with the day of rejection. The OX42 monoclonal antibody against CR3 of leukocyte-adhesion molecules inhibited hemolysis of the SPFC. Since the erythrocyte is a ligand of CR3, it is likely that hemolysis of SPFC is mediated by the CR3 adhesion molecules. In conclusion, SPFC may be an immunologic indicator of allograft rejection in rats.